HALO
Halozyme Therapeutics Inc.
Halal Rating :
Last Price
$54.79
Last updated:
Market Cap
-
7D Change
1.2%
1 Year Change
61.1%
Company Overview
Industries
Exchange
Next Earnings Date
Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes novel oncology therapies. The company's primary technology is ENHANZE®, which facilitates the delivery of injected drugs and fluids. Their business model includes licensing this drug delivery technology to pharmaceutical companies and receiving royalties from its use.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $290.08m | $131.41m | - | $4.52m | 0.00% | 3.44% |
| June 30, 2024 | $231.35m | $118.64m | - | $4.52m | 0.00% | 3.81% |
| March 31, 2024 | $195.88m | $104.84m | - | $4.51m | 0.00% | 4.30% |
Company Impact
Help us evaluate Halozyme Therapeutics Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.